BIOMAT Database Logo BIOMAT Database Logo

Dose-dependent effect of niceritrol on plasma lipoprotein-a. 1996

T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
First Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Lipoprotein-a, Lp(a), is a variant form of low density lipoprotein (LDL) that contains apolipoprotein-a, whose structure has 75-85% homology with plasminogen. Elevated plasma levels of Lp(a) are considered to be one of the independent risk factors for cardiovascular disease. We studied the effects of niceritrol, a nicotinic acid derivative, on plasma Lp(a) levels in 72 patients with hypercholesterolaemia. The dose of niceritrol was increased every 4 weeks, from 750 to 1500 and then to 2250 mg day-1. The final dose was adjusted to obtain a plasma cholesterol level less than 5.69 mmol l-1. Niceritrol led to significant decreases in plasma levels of median Lp(a), from 16.1 mg dl-1 (interquartile intervals, 8.7 to 32.8) to 11.1 mg dl-1 (interquartile intervals, 6.6 to 21), the mean reduction rate being 17.6%. In the group with pretreatment Lp(a) levels of over 20 mg dl-1, Lp(a) decreased by 10.0, 22.0 and 31.8% at the doses of 750, 1500, and 2250 mg day-1, respectively. In the group with levels less than 20 mg dl-1, only the dose of 2250 mg day-1 was effective in the reduction of Lp(a). The results suggest that the reduction of Lp(a) was dependent on the dose of niceritrol and on the pretreatment level of Lp(a). In conclusion, niceritrol is effective, in a dose-dependent manner, for reducing Lp(a) levels.

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009531 Niceritrol An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions. Pentaerythritol Tetranicotinate,Niceritrol Tetrahydrochloride,Pentaerythritoltetranicotinate,Perycit,Tetrahydrochloride, Niceritrol,Tetranicotinate, Pentaerythritol
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D017270 Lipoprotein(a) A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease. Lipoprotein (a),Lipoprotein (a-),Lipoprotein Lp(a),Lipoprotein a

Related Publications

T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
April 1997, Metabolism: clinical and experimental,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.
January 1993, Renal failure,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
February 1996, Coronary artery disease,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids.
February 1987, Atherosclerosis,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Alcohol produces dose-dependent antiatherogenic and atherogenic plasma lipoprotein responses.
May 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a).
January 1995, Clinical therapeutics,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.
June 2004, Clinical pharmacology and therapeutics,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Effect of ageing on plasma lipoprotein(a) levels.
May 2002, Annals of clinical biochemistry,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
December 2010, Clinical and experimental nephrology,
T Teramoto, and N Yamada, and H Shimano, and Y Oka, and H Itakura, and Y Saito, and N Morisaki, and K Shirai, and T Ishikawa, and N Tada, and H Ito, and T Yamanouchi, and T Matsushima, and M Kawakami, and T Murase, and M Okubo, and Y Totsuka, and M Kikuchi
Dose-dependent effect of TRH on plasma oleic acid in man.
May 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!